Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAdOx2 HAV and MVA HAV vaccines for MAP in healthy adults
NCT03027193Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Mar 2017
- Primary completion
- Jan 2020
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of ChAdOx2 HAV in Crohn's disease (6 arms), sponsored by University of Oxford. Primary endpoint: Occurrence of solicited and unsolicited local and systemic adverse events at 28 days. Started Mar 2017; status: completed.
02
Drugs
ChAdOx2 HAV
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03027193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03027193.